Independent research underscores the superior weight loss efficacy of Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic, stirring debate and market reactions
A recent study conducted by researchers in Washington and Oregon, published by JAMA, has reignited the competition between pharmaceutical giants Eli Lilly and Novo Nordisk over the efficacy of their GLP-1 drugs for weight loss. The findings indicate that Eli Lilly’s Mounjaro significantly outperforms Novo Nordisk’s Ozempic in promoting weight loss among patients.
Study Findings: A Comparative Advantage for Mounjaro
The year-long study revealed that patients treated with Novo Nordisk’s Ozempic experienced an 8% reduction in body weight, whereas those on Eli Lilly’s Mounjaro saw a remarkable 15% reduction. Furthermore, Mounjaro sustained a continuous weight loss trajectory over the year, unlike Ozempic, which showed diminished effectiveness over time. Specifically, 42% of Mounjaro patients lost 15% or more of their body weight, compared to only 18% of Ozempic patients.
Market Reactions and Corporate Responses
In response to the study, Novo Nordisk’s stock dipped over 2% on Tuesday. Novo Nordisk contended that the comparison was not entirely equitable, highlighting several deficiencies in the study’s methodology. According to a spokesperson’s statement to Yahoo Finance, the ideal comparative analysis would involve a head-to-head randomized clinical trial (RCT) focused explicitly on obesity, a scenario yet to be fully realized between tirzepatide (Mounjaro) and semaglutide (Ozempic).
Eli Lilly, while refraining from commenting directly on the study, emphasized its anticipation for the results of its ongoing SURMOUNT-5 head-to-head trial, expected to conclude later this year. This trial aims to provide a more direct comparison between the two drugs.
Implications for Advertising and Market Positioning
The study’s outcomes corroborate initial impressions from the Phase 3 trials of both companies, where Lilly’s tirzepatide demonstrated superior weight loss results compared to Novo’s semaglutide. Leveraging these findings, Eli Lilly has positioned Mounjaro in its advertising as delivering “unmatched weight reduction across all 3 doses vs Ozempic.”
Study Methodology and Limitations
Researchers utilized data from Truveta, ensuring patient anonymity, to analyze a cohort initially comprising 44,000 patients, narrowed down to over 9,000 with similar characteristics. The study included both obese and diabetic patients. Dr. F. Perry Wilson from Yale University noted potential biases, such as a healthier, wealthier, and more educated patient profile for those on Mounjaro.
Novo Nordisk criticized the study for omitting crucial variables such as insurance type, socioeconomic status, baseline BMI, and other factors that could influence weight loss outcomes. The researchers, however, defended their approach, focusing on complete and gender-specific patient information while excluding incomplete data sets.
The Financial Impact of GLP-1s
The market for GLP-1 drugs has surged, translating into billions of dollars in additional revenue for both Eli Lilly and Novo Nordisk. Wall Street projects these once-weekly injectables to contribute between $13 billion and $25 billion to the companies’ revenues this year alone, underscoring the high stakes in this pharmaceutical rivalry.
In conclusion, while Eli Lilly’s Mounjaro appears to hold a competitive edge over Novo Nordisk’s Ozempic in weight loss efficacy, the ongoing debate and future head-to-head trials will be crucial in shaping the market dynamics and patient choices in the GLP-1 drug landscape.
You might like this article:Promising Results for HyBryte in Extended Treatment of Early-Stage CTCL
